Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan-Mar;11(1):34-39.
doi: 10.4103/jhrs.JHRS_9_17.

Tamoxifen is Better than Low-Dose Clomiphene or Gonadotropins in Women with Thin Endometrium (<7 mm) after Clomiphene in Intrauterine Insemination Cycles: A Prospective Study

Sunita Sharma  1 , Geetha Rani  1 , Gunja Bose  1 , Indranil Saha  1 , Sikha Bathwal  1 , B N Chakravarty  1
Affiliations

Tamoxifen is Better than Low-Dose Clomiphene or Gonadotropins in Women with Thin Endometrium (<7 mm) after Clomiphene in Intrauterine Insemination Cycles: A Prospective Study

Sunita Sharma et al. J Hum Reprod Sci. 2018 Jan-Mar.

Abstract

Aim: Gonadotropin stimulation is used as the second line of treatment in patients with thin endometrium following clomiphene citrate (CC) administration, which is associated with higher cost, multiple births, and ovarian hyperstimulation syndrome. Tamoxifen (TMX), a selective estrogen receptor modulator, acts as an agonist on the endometrium. The objective of the present study was to compare the efficacy of low-dose CC, TMX, and gonadotropins in women with thin endometrium (<7 mm) following Clomiphene in intrauterine insemination (IUI) cycles.

Settings and design: A prospective observational study between December 2011 and June 2013 was carried out in a tertiary infertility center.

Methods: Women (n = 502) undergoing IUI with endometrium <7 mm after 100 mg CC were included in the study and divided into three treatment groups. Women in Group A (n = 182, cycles = 364) received clomiphene (50 mg/day from day 3 to 7), Group B (n = 179, cycles = 342) received TMX (40 mg/day from day 3 to 7), and Group C (n = 141, cycles = 226) received continuous urine-derived follicle-stimulating hormone 75-150 IU from day 3 onward until human chorionic gonadotropin injection. Endometrial thickness (ET), pregnancy rate, and live birth rate were considered as main outcome measures.

Statistical analysis: Multiple comparisons using one-way ANOVA and Schiff's test were performed.

Results: Pregnancy and live birth rate were significantly higher (P < 0.004) in TMX and gonadotropin groups compared to clomiphene. A number of follicles in the TMX group were found to be lower (P < 0.001) compared to other two groups. In polycystic ovary syndrome patients, ovulation induction with TMX resulted in inadequate response in more than half of the cycles.

Conclusions: TMX can improve ET and live birth rate in patients with thin endometrium after clomiphene.

Keywords: Clomiphene; gonadotropin; intrauterine insemination; tamoxifen; thin endometrium.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Number of patients, etiology, and performed intrauterine insemination cycle
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update. 2009;15:265–77. - PubMed
    1. Garcia J, Jones GS, Wentz AC. The use of clomiphene citrate. Fertil Steril. 1977;28:707–17. - PubMed
    1. Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update. 1996;2:483–506. - PubMed
    1. Nakamura Y, Ono M, Yoshida Y, Sugino N, Ueda K, Kato H, et al. Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertil Steril. 1997;67:256–60. - PubMed
    1. Homburg R. Clomiphene citrate – End of an era? A mini-review. Hum Reprod. 2005;20:2043–51. - PubMed

LinkOut - more resources